Minerva Neurosciences: Klotho Neurosciences Acquires Turn Biotechnologies to Enhance Regenerative Medicine Focus

Klotho Neurosciences Expands Focus on Regenerative Medicine through Strategic Acquisition

In a significant move within the biotechnology sector, Klotho Neurosciences, Inc. has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc. This acquisition, which includes Turn's innovative ERA (Epigenetic Reprogramming of Age) platform and the eTurna RNA delivery system, positions Klotho at the forefront of regenerative therapies targeting age-related decline. The transaction, structured as a cash and stock deal, is contingent upon due diligence and customary closing conditions. Dr. Joseph Sinkule, Klotho's CEO, emphasizes that this acquisition aligns with the company’s mission to develop therapies for diseases such as Alzheimer's and Parkinson's, which are increasingly prevalent among aging populations.

The ERA platform and eTurna system are pivotal in rejuvenating somatic cells, aiming to restore tissue function across diverse medical fields, including dermatology and immunology. This technological advancement relies on six RNA molecules, notably the Yamanaka transcription factors, which hold the potential to reset cellular age. This approach not only enhances the viability of Klotho's therapeutic initiatives but also highlights its commitment to pioneering solutions in an industry characterized by rapid growth and innovation. With an aging global population projected to reach 2.1 billion by 2050, the regenerative medicine market is increasingly critical to addressing healthcare challenges and costs, which already consume 10% of global GDP.

Furthermore, the acquisition underscores Klotho's strategic positioning as it partners with a major South Korean pharmaceutical company, valued at up to $300 million. This collaboration not only affirms the commercial viability of Turn’s technology but also enhances Klotho’s ability to leverage international markets. Following the acquisition, Klotho plans to rebrand to reflect its expanded focus and integrate Turn's management and R&D teams, thereby strengthening its competitive edge in the longevity medicine sector. As Klotho moves forward, it aims to tackle the challenges of aging and contribute meaningfully to extending healthspan, ultimately transforming how age-related diseases are approached in clinical settings.

In related developments, the longevity medicine market is expected to grow substantially in the coming years, driven by the increasing demand for solutions addressing age-related conditions. Klotho’s strategic acquisition positions the company to capitalize on this trend, providing a promising outlook for its future endeavors in regenerative health. As Klotho prepares for this transformative phase, it is well-positioned to play a crucial role in the evolution of therapies that enhance quality of life for an aging population.